Neoplastic " Black Ops": Cancer's subversive tactics in overcoming host defenses

Seminars in Cancer Biology

Volumn 22, Issue 1, 2012, Pages 50-59

  Biragyn, Arya ^a   Longo, Dan L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cancer escape; Cancer immunotherapy; Regulatory T cells; TBregs; Tregs; Tumor evoked regulatory B cells

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

AUTOIMMUNITY; B LYMPHOCYTE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESEARCH; CHEMOKINESIS; EFFECTOR CELL; EVIDENCE BASED MEDICINE; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ESCAPE; TUMOR PROMOTION; TUMOR VASCULARIZATION;

B-LYMPHOCYTES, REGULATORY; CHEMOKINES; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84857141464     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.01.005     Document Type: Review

References (171)

1. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1-27.
2. Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst 2010, 102(9):605-613.
3. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
4. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353(25):2654-2666.
5. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26(32):5233-5239.
6. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009, 21(2):200-208.
7. Sahin U., Tureci O., Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997, 9(5):709-716.
8. Brichard V., Van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178(2):489-495.
9. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998, 187(2):265-270.
10. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997, 94(5):1914-1918.
11. Coggin J.H., Barsoum A.L., Rohrer J.W. 37kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res 1999, 19(6C):5535-5542.
12. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5(6):677-685.
13. Rosenberg S.A. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001, 250(6):462-475.
14. Wang R.F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001, 22(5):269-276.
15. Wang H.Y., Lee D.A., Peng G., Guo Z., Li Y., Kiniwa Y., et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004, 20(1):107-118.
16. Xie Y., Akpinarli A., Maris C., Hipkiss E.L., Lane M., Kwon E.K., et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010, 207(3):651-667.
17. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112(2):362-373.
18. Quezada S.A., Simpson T.R., Peggs K.S., Merghoub T., Vider J., Fan X., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010, 207(3):637-650.
19. Saxton M.L., Longo D.L., Wetzel H.E., Tribble H., Alvord W.G., Kwak L.W., et al. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood 1997, 89(7):2529-2536.
20. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9(5):503-510.
21. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16(2):91-102.
22. Tao K., Fang M., Alroy J., Sahagian G.G. Imagable 4T1 model for the study of late stage breast cancer (translated from eng). BMC Cancer 2008, 8:228. [in English].
23. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007, 67(19):9518-9527.
24. DuPre S.A., Hunter K.W. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol 2007, 82(1):12-24.
25. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006, 25(3):315-322.
26. Nagaraj S., Gabrilovich D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008, 68(8):2561-2563.
27. Khong H.T., Wang Q.J., Rosenberg S.A. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004, 27(3):184-190.
28. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
29. Kacha A.K., Fallarino F., Markiewicz M.A., Gajewski T.F. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol 2000, 165(11):6024-6028.
30. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9(4):212.
31. Reome J.B., Hylind J.C., Dutton R.W., Dobrzanski M.J. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol 2004, 111(1):69-81.
32. Ghosh P., Komschlies K.L., Cippitelli M., Longo D.L., Subleski J., Ye J., et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995, 87(19):1478-1483.
33. Langenkamp A., Messi M., Lanzavecchia A., Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000, 1(4):311-316.
34. Sander B., Skansen-Saphir U., Damm O., Hakansson L., Andersson J., Andersson U. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guerin. Immunology 1995, 86(4):512-518.
35. Olkhanud P.B., Rochman Y., Bodogai M., Malchinkhuu E., Wejksza K., Xu M., et al. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol 2011, 186(10):5656-5662.
36. Pedroza-Gonzalez A., Xu K., Wu T.C., Aspord C., Tindle S., Marches F., et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011, 208(3):479-490.
37. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011, 208(3):469-478.
38. Al-Shami A., Spolski R., Kelly J., Keane-Myers A., Leonard W.J. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 2005, 202(6):829-839.
39. He R., Oyoshi M.K., Garibyan L., Kumar L., Ziegler S.F., Geha R.S. TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci U S A 2008, 105(33):11875-11880.
40. Olkhanud P.B., Damdinsuren B., Bodogai M., Gress R.E., Sen R., Wejksza K., et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T regulatory cells. Cancer Res 2011.
41. Meyer E.H., Wurbel M.A., Staton T.L., Pichavant M., Kan M.J., Savage P.B., et al. iNKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity. J Immunol 2007, 179(7):4661-4671.
42. Kim R., Emi M., Tanabe K., Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006, 66(11):5527-5536.
43. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000, 1(6):515-520.
44. Gondek D.C., Lu L.F., Quezada S.A., Sakaguchi S., Noelle R.J. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005, 174(4):1783-1786.
45. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21(4):589-601.
46. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258(5089):1795-1798.
47. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
48. Cho M., Cummings R.D. Characterization of monomeric forms of galectin-1 generated by site-directed mutagenesis. Biochemistry 1996, 35(40):13081-13088.
49. Camby I., Le M.M., Lefranc F., Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006, 16(11):137R-157R.
50. Elola M.T., Chiesa M.E., Alberti A.F., Mordoh J., Fink N.E. Galectin-1 receptors in different cell types. J Biomed Sci 2005, 12(1):13-29.
51. Ravatn R., Wells V., Nelson L., Vettori D., Mallucci L., Chin K.V. Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine. Cancer Res 2005, 65(5):1631-1634.
52. Novelli F., Allione A., Wells V., Forni G., Mallucci L. Negative cell cycle control of human T cells by beta-galactoside binding protein (beta GBP): induction of programmed cell death in leukaemic cells. J Cell Physiol 1999, 178(1):102-108.
53. Wells V., Downward J., Mallucci L. Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation. Oncogene 2007, 26(55):7709-7714.
54. Ochoa A.C., Longo D.L. Alteration of signal transduction in T cells from cancer patients. Important Adv Oncol 1995, 43-54.
55. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011.
56. Baatar D., Olkhanud P., Newton D., Sumitomo K., Biragyn A. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol 2007, 179(3):1996-2004.
57. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101(5):455-458.
58. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155(3):1151-1164.
59. Alyanakian M.A., You S., Damotte D., Gouarin C., Esling A., Garcia C., et al. Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A 2003, 100(26):15806-15811.
60. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199(7):971-979.
61. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168(9):4272-4276.
62. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106(6):2018-2025.
63. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-949.
64. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4(4):330-336.
65. Baatar D., Olkhanud P., Sumitomo K., Taub D., Gress R., Biragyn A. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs, unprimed CCR4-Tregs regulate effector T cells using FasL. J Immunol 2007, 178(8):4891-4900.
66. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193(11):1285-1294.
67. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998, 187(1):129-134.
68. Stephens L.A., Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol 2000, 165(6):3105-3110.
69. Cavani A., Nasorri F., Prezzi C., Sebastiani S., Albanesi C., Girolomoni G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 2000, 114(2):295-302.
70. Zheng S.G., Wang J., Wang P., Gray J.D., Horwitz D.A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007, 178(4):2018-2027.
71. Serafini P., De S.C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004, 53(2):64-72.
72. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66(2):1123-1131.
73. Olkhanud P.B., Baatar D., Bodogai M., Hakim F., Gress R., Anderson R.L., et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009, 69(14):5996-6004.
74. Okudaira K., Hokari R., Tsuzuki Y., Okada Y., Komoto S., Watanabe C., et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009, 35(4):741-749.
75. Phares T.W., Ramakrishna C., Parra G.I., Epstein A., Chen L., Atkinson R., et al. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J Immunol 2009, 182(9):5430-5438.
76. Probst H.C., McCoy K., Okazaki T., Honjo T., van den B.M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005, 6(3):280-286.
77. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389(6652):737-742.
78. Annacker O., Pimenta-Araujo R., Burlen-Defranoux O., Barbosa T.C., Cumano A., Bandeira A., et al. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001, 166(5):3008-3018.
79. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007, 8(12):1380-1389.
80. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450(7169):566-569.
81. Levings M.K., Roncarolo M.G. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 2000, 106(1 Pt 2):S109-S112.
82. Shevach E.M. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001, 193(11):F41-F46.
83. Baatar D., Olkhanud P.B., Wells V., Indig F.E., Mallucci L., Biragyn A. Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferation. Brain Behav Immun 2009, 23(7):1028-1037.
84. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006, 176(3):1582-1587.
85. Barao I., Hanash A.M., Hallett W., Welniak L.A., Sun K., Redelman D., et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006, 103(14):5460-5465.
86. Giroux M., Yurchenko E., St-Pierre J., Piccirillo C.A., Perreault C. T regulatory cells control numbers of NK cells and CD8alpha+ immature dendritic cells in the lymph node paracortex. J Immunol 2007, 179(7):4492-4502.
87. Terme M., Chaput N., Combadiere B., Ma A., Ohteki T., Zitvogel L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol 2008, 180(7):4679-4686.
88. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34(2):336-344.
89. Bose A., Chakraborty T., Chakraborty K., Pal S., Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008, 8:10.
90. varo-Naranjo T., Lejeune M., Salvado-Usach M.T., Bosch-Princep R., Reverter B., Jaen-Martinez J., et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005, 46(11):1581-1591.
91. Milasiene V., Stratilatovas E., Norkiene V., Jonusauskaite R. Lymphocyte subsets in peripheral blood as prognostic factors in colorectal cancer. J BUON 2005, 10(2):261-264.
92. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000, 356(9244):1795-1799.
93. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(5562):2097-2100.
94. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181(8):5791-5802.
95. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., et al. Tumor evasion of the immune system by converting CD4+. J Immunol 2007, 178(5):2883-2892.
96. Verhagen J., Gabrysova L., Minaee S., Sabatos C.A., Anderson G., Sharpe A.H., et al. Enhanced selection of FoxP3+ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease. Proc Natl Acad Sci U S A 2009, 106(9):3306-3311.
97. Sugihara A.Q., Rolle C.E., Lesniak M.S. Regulatory T cells actively infiltrate metastatic brain tumors. Int J Oncol 2009, 34(6):1533-1540.
98. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol Med 2004, 10(1):15-18.
99. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281(5380):1191-1193.
100. Smyth M.J., Godfrey D.I. NKT cells and tumor immunity - a double-edged sword. Nat Immunol 2000, 1(6):459-460.
101. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198(11):1741-1752.
102. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005, 65(24):11743-11751.
103. Sinha P., Clements V.K., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005, 174(2):636-645.
104. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111(8):4233-4244.
105. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65(8):3044-3048.
106. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64(16):5839-5849.
107. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002, 168(2):689-695.
108. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69(4):1553-1560.
109. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25(18):2546-2553.
110. DuPre S.A., Redelman D., Hunter K.W. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007, 88(5):351-360.
111. Danna E.A., Sinha P., Gilbert M., Clements V.K., Pulaski B.A., Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004, 64(6):2205-2211.
112. Elpek K.G., Lacelle C., Singh N.P., Yolcu E.S., Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007, 178(11):6840-6848.
113. Pan P.Y., Ma G., Weber K.J., Ozao-Choy J., Wang G., Yin B., et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010, 70(1):99-108.
114. Muller A., Sonkoly E., Eulert C., Gerber P.A., Kubitza R., Schirlau K., et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006, 118(9):2147-2157.
115. Zhou Y., Larsen P.H., Hao C., Yong V.W. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002, 277(51):49481-49487.
116. Sanchez-Sanchez N., Riol-Blanco L., de la R.G., Puig-Kroger A., Garcia-Bordas J., Martin D., et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 2004, 104(3):619-625.
117. Cronshaw D.G., Owen C., Brown Z., Ward S.G. Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J Immunol 2004, 172(12):7761-7770.
118. Addison C.L., Arenberg D.A., Morris S.B., Xue Y.Y., Burdick M.D., Mulligan M.S., et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000, 11(2):247-261.
119. Salcedo R., Resau J.H., Halverson D., Hudson E.A., Dambach M., Powell D., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000, 14(13):2055-2064.
120. Okamatsu Y., Kim D., Battaglino R., Sasaki H., Spate U., Stashenko P. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol 2004, 173(3):2084-2090.
121. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001, 2(2):123-128.
122. Sica A., Saccani A., Bottazzi B., Bernasconi S., Allavena P., Gaetano B., et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 2000, 164(2):733-738.
123. Frederick M.J., Henderson Y., Xu X., Deavers M.T., Sahin A.A., Wu H., et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 2000, 156(6):1937-1950.
124. Shurin G.V., Ferris R.L., Tourkova I.L., Perez L., Lokshin A., Balkir L., et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 2005, 174(9):5490-5498.
125. Kohrgruber N., Groger M., Meraner P., Kriehuber E., Petzelbauer P., Brandt S., et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J Immunol 2004, 173(11):6592-6602.
126. Ogilvie P., Paoletti S., Clark-Lewis I., Uguccioni M. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 2003, 102(3):789-794.
127. Vianello F., Papeta N., Chen T., Kraft P., White N., Hart W.K., et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol 2006, 176(5):2902-2914.
128. Gu L., Tseng S., Horner R.M., Tam C., Loda M., Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404(March (6776)):407-411.
129. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6(8):3282-3289.
130. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
131. Mullins I.M., Slingluff C.L., Lee J.K., Garbee C.F., Shu J., Anderson S.G., et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004, 64(21):7697-7701.
132. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010, 237(1):264-283.
133. von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99(9):3319-3325.
134. Sorrentino R., Morello S., Forte G., Montinaro A., De Vita G., Luciano A., et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med 2011, 183(10):1369-1379.
135. Carpenter E.L., Mick R., Rech A.J., Beatty G.L., Colligon T.A., Rosenfeld M.R., et al. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced me lanoma and other cancers. Clin Cancer Res 2009, 15(13):4277-4287.
136. Barbera-Guillem E., Nelson M.B., Barr B., Nyhus J.K., May K.F., Feng L., et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother: CII 2000, 48(10):541-549.
137. Brodt P., Gordon J. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 1978, 121(1):359-362.
138. Brodt P., Gordon J. Natural resistance mechanisms may play a role in protection against chemical carcinogenesis. Cancer Immunol Immunother: CII 1982, 13(2):125-127.
139. Monach P.A., Schreiber H., Rowley D.A. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 1993, 55(6):1356-1361.
140. Firestein G.S. Evolving concepts of rheumatoid arthritis (translated from eng). Nature 2003, 423(6937):356-361. [in English].
141. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011, 17(5):610-617.
142. Zusman T., Lisansky E., Arons E., Anavi R., Bonnerot C., Sautes C., et al. Contribution of the intracellular domain of murine Fc-gamma receptor type IIB1 to its tumor-enhancing potential. Int J Cancer 1996, 68(2):219-227.
143. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7(5):411-423.
144. Stach R.M., Rowley D.A. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens. J Exp Med 1993, 178(3):841-852.
145. Rowley D.A., Stach R.M. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol 1998, 10(3):355-363.
146. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464(7286):302-305.
147. Wong S.C., Puaux A.L., Chittezhath M., Shalova I., Kajiji T.S., Wang X., et al. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 2010, 40(8):2296-2307.
148. Qin Z., Richter G., Schuler T., Ibe S., Cao X., Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998, 4(5):627-630.
149. Wu H.Y., Monsonego A., Weiner H.L. The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression. J Autoimmun 2006, 26(2):116-126.
150. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28(5):639-650.
151. Shimomura Y., Mizoguchi E., Sugimoto K., Kibe R., Benno Y., Mizoguchi A., et al. Regulatory role of B-1 B cells in chronic colitis. Int Immunol 2008, 20(6):729-737.
152. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16(2):219-230.
153. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32(1):129-140.
154. Byrne S.N., Halliday G.M. B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J Invest Dermatol 2005, 124(3):570-578.
155. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008, 118(10):3420-3430.
156. Fuchs E.J., Matzinger P. B cells turn off virgin but not memory T cells. Science 1992, 258(5085):1156-1159.
157. Hussain S., Delovitch T.L. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007, 179(11):7225-7232.
158. Roosnek E., Burjanadze M., Dietrich P.Y., Matthes T., Passweg J., Huard B. Tumors that look for their springtime in APRIL. Crit Rev Oncol Hematol 2009, 72(2):91-97.
159. Pelekanou V., Kampa M., Kafousi M., Darivianaki K., Sanidas E., Tsiftsis D.D., et al. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer 2008, 8:76.
160. Aklilu M., Stadler W.M., Markiewicz M., Vogelzang N.J., Mahowald M., Johnson M., et al. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2004, 15(7):1109-1114.
161. Matzinger P. An innate sense of danger. Semin Immunol 1998, 10(5):399-415.
162. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996, 97(12):2792-2802.
163. Luan J., Shattuck-Brandt R., Haghnegahdar H., Owen J.D., Strieter R., Burdick M., et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997, 62(5):588-597.
164. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002, 161(1):125-134.
165. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996, 184(3):981-992.
166. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002, 2(2):106-115.
167. Takenaga M., Tamamura H., Hiramatsu K., Nakamura N., Yamaguchi Y., Kitagawa A., et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004, 320(1):226-232.
168. Miwa S., Mizokami A., Keller E.T., Taichman R., Zhang J., Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005, 65(19):8818-8825.
169. Biragyn A., Schiavo R., Olkhanud P., Sumitomo K., King A., McCain M., et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity. J Immunol 2007, 179(2):1381-1388.
170. Schiavo R., Baatar D., Olkhanud P., Indig F.E., Restifo N., Taub D., et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006, 107(12):4597-4605.
171. Biragyn A., Surenhu M., Yang D., Ruffini P.A., Haines B.A., Klyushnenkova E., et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001, 167(11):6644-6653.